Table 1.
The dosage and approach of drugs.
| Study | EINSTEIN 14 | SELECT-D 15 | XALIA 19 | Yang 20 |
|---|---|---|---|---|
| Year | 2014 | 2018 | 2017 | 2019 |
| Center | multicenter | multicenter | multicenter | singlecenter |
| Follow-up | >180 d | 24 m | >3 m | 6 m |
| Patients | 491/440 | 203/203 | 146/441 | 36/36 |
| Male | 272/232 | 116/98 | 76/218 | 19/20 |
| Cancers | ||||
| Genitourinary tract | 157/137 | 25/17 | 38/137 | 0/1 |
| Gastrointestinal | 65/52 | 91/86 | 20/96 | 3/7 |
| Breast | 67/71 | 20/20 | 32/82 | 5/4 |
| Haematological | 52/37 | 14/17 | 12/38 | 2/1 |
| Lung | 24/16 | 22/25 | 5/39 | 9/6 |
| Skin | 67/70 | 2/0 | 6/12 | NA |
| CNS brain | 4/4 | 1/2 | 5/11 | NA |
| Gynecologic | NA | 18/25 | NA | 17/15 |
| Combinations | 25/30 | NA | NA | NA |
| Others | 30/23 | 10/11 | 36/56 | 0/2 |
| Recurrent VTE | 11/13 | 8/18 | 5/19 | 4/3 |
| Adverse bleeding events | 6/12 | 11/6 | 2/17 | 0/0 |
| Clinically relevant bleeding | 55/49 | 25/7 | 67/244 | 5/3 |
| All-cause mortality | 43/40 | 33/28 | 7/68 | NA |
| Net clinical benefit | 21/28 | NA | NA | NA |
| Safety population | 488/438 | NA | NA | NA |
NA: not applicable.
Genitourinary tract (including bladder or Prostate); Skin (including squamous-cell or basal-cell carcinoma); Gynecologic (including ovarian)